{"entity":{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","aka":[],"tldr":"Xavier Pivot represents Institut Strauss in the Organisation of European Cancer Institutes, which lists the organisation among its members in France.","summary":"Xavier Pivot is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Strauss, its full member in France. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Xavier_Pivot","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Strauss website","url":"https://www.institut-strauss.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-strauss"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Strauss to the Organisation of European Cancer Institutes","institutionId":"institut-strauss","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Strauss website","url":"https://www.institut-strauss.fr/"}],"papers":[{"title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","journal":"JAMA Oncol","year":2020,"url":"https://doi.org/10.1001/jamaoncol.2019.4782","doi":"10.1001/jamaoncol.2019.4782","note":"Europe PMC author record matched by affiliation"},{"title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","journal":"Ann Oncol","year":2024,"url":"https://doi.org/10.1016/j.annonc.2024.04.013","doi":"10.1016/j.annonc.2024.04.013","note":"Europe PMC author record matched by affiliation"},{"title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","journal":"Lancet","year":2019,"url":"https://doi.org/10.1016/s0140-6736(19)30653-1","doi":"10.1016/s0140-6736(19)30653-1","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-3689-5013"},"route":"/people/xavier-pivot/","neighbours":{"institution":[{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}]}}